Endometrium Cancer Clinical Trial
Official title:
Stratifying Endometrial Cancer Patients Using a PET/MRI Prognostic Model
Endometrial cancer (EC) is the most common gynecological malignancy in high-income countries. Prognosis and treatment are dictated by cancer histological subtype and grade coupled with surgical staging as described by Surgical International Federation of Gynecology and Obstetrics (FIGO) staging system. Surgery is the elective standard treatment and used for staging of EC. The purpose of this study is to collect images from a simultaneous PET/MRI study from which to extrapolate a preoperative, non-invasive, prognostic model.
Magnetic resonance imaging (MRI) is the most frequently used imaging tool in preoperative staging of endometrial cancer. FDG-PET has demonstrated higher sensitivity than MRI in detecting nodal involvement and metastatic disease and is currently used in adjunction to MRI. Distinct MRI and FDG-PET parameters correlate well with tumor aggressiveness and can and have been used as prognostic factors. The Investigators believe that the combination of data from these two imaging techniques, from which different derived tumor features can be extrapolated, can stratify patients in high-risk and low-risk groups already preoperatively. The aim of combined techniques is to collect large amounts of data leveraging advantages of both modalities (MR's strengths in local staging and PET's strengths in nodal staging) in a single scan from which to extrapolate a preoperative, non-invasive, prognostic model. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05036681 -
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
|
Phase 2 | |
Completed |
NCT00377520 -
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT05902988 -
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06192017 -
Development of a Molecular Diagnostic Tool for Endometrial Cancer.
|
||
Completed |
NCT03899441 -
Multimedia Aid Gynecologic Counseling and Consent
|
N/A | |
Completed |
NCT02552121 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02001623 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02997553 -
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
|
Phase 3 | |
Suspended |
NCT03095664 -
Effect of a Lifestyle Intervention on Nutritional Status and Prognosis of Endometrial Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT01466777 -
Endometrial Cancer and Robotic-assisted Versus Traditional Laparoscopy
|
N/A | |
Completed |
NCT01068483 -
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
|
Phase 1 | |
Recruiting |
NCT03896113 -
Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT03570866 -
PET/CT in the Management of Patients With Early Stage Endometrial Cancer
|
||
Completed |
NCT05246462 -
The Effect of Logotherapy on Mental Health in Gynecological Cancer Patients
|
N/A | |
Withdrawn |
NCT04464967 -
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
|
Phase 1/Phase 2 | |
Recruiting |
NCT05651282 -
Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer
|
Phase 4 | |
Completed |
NCT06187558 -
Suspension of the Pelvic and Abdominal Organs During Minimally Invasive Surgery
|
||
Completed |
NCT06312917 -
Effect of Physical Activity Intervention on Overweight and Obese Patients With Endometrial Cancer
|
N/A | |
Active, not recruiting |
NCT03951415 -
Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT02221076 -
Probe-based and Needle-based Confocal Laser Endomicroscopy During Gynaecological Procedures.
|
N/A |